#1 Clinical Trials Search in Europe

Teriflunomide

Teriflunomide, marketed under the brand name Aubagio, is an oral medication that has shown promise in the treatment of multiple sclerosis (MS) and other autoimmune conditions. This article explores the use of teriflunomide in various clinical trials, examining its efficacy, safety, and potential benefits for patients with relapsing forms of MS and other disorders.

Table of Contents

What is Teriflunomide?

Teriflunomide is a medication used to treat certain types of multiple sclerosis (MS). It’s also known by its brand name Aubagio[1]. Teriflunomide is the primary metabolite (breakdown product) of another drug called leflunomide, which is used to treat rheumatoid arthritis[2].

What Conditions Does Teriflunomide Treat?

Teriflunomide is primarily used to treat relapsing forms of multiple sclerosis (MS), including:

  • Relapsing-Remitting Multiple Sclerosis (RRMS): This is the most common form of MS, characterized by periods of symptom flare-ups followed by periods of recovery[1].
  • Active Secondary Progressive Multiple Sclerosis (SPMS): A form of MS that can develop in some people with RRMS, where disability progressively worsens[3].
Interestingly, research is also being conducted to explore the potential use of teriflunomide in treating other conditions, such as:
  • HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): A rare neurological condition caused by a virus[4].
  • Immune Thrombocytopenia: A blood disorder characterized by a low platelet count[5].

How Does Teriflunomide Work?

Teriflunomide works by modulating (adjusting) the immune system. Specifically, it:

  • Inhibits an enzyme called dihydroorotate dehydrogenase (DHODH): This enzyme is crucial for the rapid growth of certain immune cells (lymphocytes) that are involved in MS[2].
  • Reduces inflammation: By limiting the growth of certain immune cells, teriflunomide helps reduce the inflammation that damages nerve cells in MS[1].
  • Affects T-cell and B-cell function: These are types of white blood cells involved in the immune response. Teriflunomide may alter their behavior, which could contribute to its therapeutic effects[3].
By these mechanisms, teriflunomide helps to slow down the progression of MS and reduce the frequency of relapses.

How is Teriflunomide Administered?

Teriflunomide is taken orally (by mouth) as a tablet. The typical dosage is:

  • 14 mg once daily: This is the most common dose for adults with relapsing forms of MS[1].
  • 7 mg once daily: This dose may be used in some cases, particularly if there are concerns about side effects[6].
It’s important to take teriflunomide exactly as prescribed by your healthcare provider. The medication is usually taken long-term to manage MS effectively.

Efficacy of Teriflunomide

Clinical trials have shown that teriflunomide can be effective in managing relapsing forms of MS. Some key findings include:

  • Reduced relapse rate: Teriflunomide has been shown to lower the number of MS relapses patients experience[1].
  • Slowed disability progression: Some studies have found that teriflunomide can slow the worsening of disability in MS patients[1].
  • Reduced MRI activity: Teriflunomide has been shown to reduce the number of new or enlarging brain lesions seen on MRI scans[6].
It’s important to note that the effectiveness can vary from person to person, and your healthcare provider will monitor your response to the medication.

Side Effects and Safety

Like all medications, teriflunomide can cause side effects. Common side effects may include:

  • Headache
  • Diarrhea
  • Nausea
  • Hair thinning or hair loss
  • Elevated liver enzymes[7]
More serious side effects, though less common, can include:
  • Liver problems
  • Low white blood cell count, which can increase the risk of infections
  • High blood pressure
Your healthcare provider will monitor you closely for these side effects through regular check-ups and blood tests. It’s crucial to report any unusual symptoms or side effects to your doctor promptly.

Impact on Quality of Life

Several studies have looked at how teriflunomide affects patients’ quality of life. Findings suggest that:

  • Improved daily activities: Some patients report improvements in their ability to perform daily activities[8].
  • Convenience: As an oral medication, teriflunomide may be more convenient for some patients compared to injectable MS treatments[8].
  • Fatigue management: Some studies have examined teriflunomide’s impact on MS-related fatigue, which is a common and debilitating symptom[9].
However, experiences can vary, and it’s important to discuss your personal goals and concerns with your healthcare provider.

Ongoing Research

Research on teriflunomide is ongoing, with scientists exploring:

  • Long-term effects: Studies are looking at the long-term safety and efficacy of teriflunomide in MS patients[9].
  • Biomarkers: Researchers are investigating whether certain biological markers can predict how well a patient will respond to teriflunomide[3].
  • Use in other conditions: As mentioned earlier, teriflunomide is being studied for potential use in conditions other than MS[4][5].
These ongoing studies may provide more insights into how teriflunomide works and how it can be used most effectively to help patients with MS and potentially other conditions.

Aspect Details
Primary Conditions Studied Relapsing-Remitting Multiple Sclerosis (RRMS), HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), Immune Thrombocytopenia
Dosage Typically 7 mg or 14 mg oral tablets, administered daily
Primary Outcomes Measured Reduction in MS relapses, changes in MRI lesions, disability progression (EDSS scores), patient-reported outcomes, safety and tolerability
Secondary Outcomes Quality of life measures, cognitive function, biomarker analysis, long-term safety and efficacy
Study Designs Phase II and IV trials, observational studies, open-label studies, single-arm studies
Duration of Studies Ranging from 24 weeks to 2 years, with some long-term extension studies
Key Safety Monitoring Liver function tests, complete blood count, adverse event reporting

FAQ

  • What is teriflunomide and how does it work? Teriflunomide is an oral medication used to treat relapsing forms of multiple sclerosis. It works by inhibiting an enzyme called dihydroorotate dehydrogenase (DHODH), which is involved in the rapid growth of immune cells. This helps reduce inflammation and nerve damage in MS patients.
  • What conditions are being studied with teriflunomide in clinical trials? While primarily studied for multiple sclerosis, clinical trials are also exploring teriflunomide's potential in treating other conditions such as HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) and immune thrombocytopenia.
  • What are the common side effects of teriflunomide? Common side effects of teriflunomide may include headache, diarrhea, nausea, hair thinning, and elevated liver enzymes. However, the safety profile is being closely monitored in clinical trials.
  • How is teriflunomide administered in clinical trials? In most clinical trials, teriflunomide is administered orally as a daily tablet, typically at doses of 7 mg or 14 mg, depending on the study protocol and patient needs.
  • What are researchers hoping to learn from these clinical trials? Researchers are aiming to better understand teriflunomide's efficacy in reducing MS relapses and disability progression, its long-term safety profile, its effects on quality of life, and its potential applications in other autoimmune conditions.

Ongoing Clinical Trials on Teriflunomide

  • Study on Stopping Dimethyl Fumarate and Drug Combination in Patients Aged 55+ with Inactive Relapsing-Remitting Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study on Long-Term Safety of Tolebrutinib for Patients with Relapsing or Progressive Multiple Sclerosis

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark The Netherlands

  • Study on Anti-CD20 Therapy and Drug Combination for Patients with Relapsing-Remitting Multiple Sclerosis

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia Czechia Estonia France Germany +9

  • Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Denmark Ireland +7

  • Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on Stopping Disease-Modifying Therapies in Inactive Secondary Progressive Multiple Sclerosis Patients Over 50 Using Glatiramer Acetate and Drug Combination

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of Frexalimab and Teriflunomide in Adults with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Bulgaria Croatia Czechia Denmark France +10

Glossary

  • Teriflunomide: An oral medication used to treat relapsing forms of multiple sclerosis, which works by inhibiting the enzyme dihydroorotate dehydrogenase (DHODH) to reduce inflammation and nerve damage.
  • Multiple Sclerosis (MS): A chronic autoimmune disease that affects the central nervous system, causing inflammation and damage to the protective covering of nerve fibers.
  • Relapsing-Remitting Multiple Sclerosis (RRMS): The most common form of MS characterized by clearly defined attacks of new or increasing neurologic symptoms, followed by periods of partial or complete recovery.
  • HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): A rare neurological condition caused by the human T-cell lymphotropic virus type 1 (HTLV-1), leading to progressive weakness in the lower limbs.
  • Immune Thrombocytopenia: A blood disorder characterized by a decrease in the number of platelets in the blood, leading to an increased risk of bleeding.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis patients, ranging from 0 to 10 in 0.5 unit increments.
  • Magnetic Resonance Imaging (MRI): A medical imaging technique used to produce detailed images of the body's organs and tissues, often used to monitor MS disease activity and progression.
  • Gadolinium-enhancing lesions: Areas of active inflammation in the brain or spinal cord that can be seen on MRI scans after the injection of a contrast agent called gadolinium.
  • Disease-Modifying Therapy (DMT): Medications designed to reduce the frequency and severity of MS relapses and slow the progression of the disease.
  • Progressive Multifocal Leukoencephalopathy (PML): A rare but serious brain infection that can occur in some patients taking certain MS medications, particularly those affecting the immune system.

References

  1. https://clinicaltrials.gov/study/NCT03856619
  2. https://clinicaltrials.gov/study/NCT01970410
  3. https://clinicaltrials.gov/study/NCT03561402
  4. https://clinicaltrials.gov/study/NCT04799288
  5. https://clinicaltrials.gov/study/NCT06190145
  6. https://clinicaltrials.gov/study/NCT01487096
  7. https://clinicaltrials.gov/study/NCT04410965
  8. https://clinicaltrials.gov/study/NCT01895335
  9. https://clinicaltrials.gov/study/NCT02490982